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Does basal type breast cancer arise from oncogenic transformation of a basal cell type? In this issue of Cell
Stem Cell, Molyneux et al. (2010) investigate the provenance of the basal-type BRCA1 breast carcinoma and
come up with unanticipated results.Breast cancer is a diverse disease that
can be categorized into at least six
clinically relevant subtypes based upon
molecular gene signatures. The subtypes
fit into the broader groupings of either
‘‘basal’’ or ‘‘luminal’’ types because of
their molecular similarity to the basal or
luminal cells of the normal mammary
gland. Thus, basal-type breast cancers
express high levels of basal cell markers
(cytokeratins 5/6, 14, and 17), whereas
luminal-type breast cancers are defined
by high expression of luminal cell markers
(estrogen receptor alpha, cytokeratins
8/18, and GATA3-binding protein) (Sorlie
et al., 2003). Such parallels suggest that
the biology of the target cell of oncogenic
transformation is echoed in the disease
that ensues. Put simply, basal-type breast
cancers would seem to arise from trans-
formed mammary basal progenitor cells
and luminal-type breast cancers from
transformed luminal progenitor cells
(Petersen and Polyak, 2010).
BRCA1 is a tumor suppressor gene that
is often mutated in the germ line, giving
rise to greatly elevated risk of developing
basal-type breast carcinoma. Previous
work had proposed that BRCA1 is an
important regulator of mammary stem
cell fate and that breast tissues from
women with germline BRCA1 mutations
had an expansion of BRCA1 mutant
mammary stem/progenitor cells (Liu
et al., 2008). Furthermore, K14-Cre
Brca1f/f p53f/f transgenic mice with
targeted deletion of BRCA1 to mammary
basal cells developed basal-like tumors
with features of BRCA1 mutant breast
carcinomas (Liu et al., 2007). As such,
BRCA1mutant breast cancerwas thought
to arise from a basal progenitor/stem cell.A recent flow of papers, however, call
this notion into question. In this issue of
Cell Stem Cell, Molyneux et al. (2010)
took a novel approach to define the cell
of origin for BRCA1mutant breast cancer.
They analyzed a conditional mousemodel
of BRCA1 deficiency, in which Cre recom-
binase-dependent deletion of exons en-
coding the C terminus of the BRCA1
protein combined with p53 heterozy-
gosity lead to tumor formation. Pertinent
to this model, Cre expression was driven
by the Beta lactoglobulin (Blg) promoter
and is therefore confined to a subpopula-
tion of mammary epithelial cells. Impor-
tantly, the Blg-Cre Brca1f/f p53+/ trans-
genic mice developed mammary tumors
that closely resembled human BRCA1
mutant breast cancer. Accordingly, iden-
tifying the phenotype of the Blg-positive
cells in themousemammary gland should
shed light on the cell of origin for BRCA1
basal-type breast carcinoma.
To that end, the authors used cell-
surface antigen profiles to distinguish
threedifferentmammaryepithelial popula-
tions. They demonstrated that Blg activity
is most evident in a CD24+/High Sca-1
ERcell population, thusdefininga luminal
ER progenitor cell as the cell of origin
for BRCA1 mutant basal-like tumors
(Figure 1).
This novel work is at odds with the
previous contention that BRCA1 mutant
tumors arise from a mammary basal cell
(Liu et al., 2007). To further address these
conflicting data, Molyneux et al. (2010)
also presents findings directly comparing
tumors arising from Blg-Cre Brca1f/f
p53+/ or an independently constructed
line of K14-Cre Brca1f/f p53+/ transgenic
mice. They arrive at the conclusion thatCell Stem Cell 7, Stheir K14-Cre Brca1f/f p53+/ transgenic
mice developed metaplastic carcinoma
or malignant adenomyoepithelioma (both
rare types of breast cancer), and not
a disease reminiscent of BRCA1-muta-
tion. It is possible that the differences in
these two studies are due to subtleties in
experimental design (e.g., floxed p53
allele versus p53 heterozygote back-
ground, different K14-Cre transgenes or
floxed Brca1 alleles) that may have lead
to oncogenic transformation of different
target cell populations within the mam-
mary gland.
In fact, identifying specific target
populations in the normal mammary gland
remains a daunting challenge, given
the dearth of useful stem-cell-specific
markers. Thus, current cellular classifica-
tions rely heavily uponcell-surface antigen
profiling, which results at best in enrich-
ment of target cells rather than isolation
of homogenous populations. For ex-
ample, the CD49fhiCD29hiCD24+Sca1
murine mammary stem cell identifier
enriches for a cell population of which
less than 5% are actually mammary stem
cells (Visvader, 2009). Given these limita-
tions, themost definitivemeans of assign-
ing mammary cell phenotype is by
functionally assessing a cell’s ability to
repopulate a cleared mouse mammary
stromal fat pad. In this assay, mammary
stem cells, and to a lesser extent bipotent
progenitor cells, generate epithelial out-
growths containing basal and luminal
cell lineages. It is therefore somewhat
surprising that the luminal ER progenitor
cells defined in theMolyneux study, which
seem firmly committed to enter and
remain within the luminal differentiation
lineage, actually generated epithelialeptember 3, 2010 ª2010 Elsevier Inc. 271
MAMMARY STEM CELL HIERARCHY
basal 
progenitor 
luminal ER-
progenitor 
(CD24+/HighSca1-)
diﬀerenated 
luminal cells
BASAL-TYPE BREAST CARCINOMA
BRCA1
mutaon
aberrant basal  
progenitor
diﬀerenated 
basal cells
stem
cell
bipotent
progenitor
?
Figure 1. Schematic Diagram of a Mammary Stem Cell Hierarchy
In this diagram, a luminal ER progenitor cell (CD24+/HighSca1ER) acquires
a BRCA1 mutation and subsequently transitions into an aberrant basal
progenitor cell (or directly differentiates into aberrant basal-like cells) and
thus gives rise to BRCA1 mutant basal-like breast carcinoma. It is also
possible that luminal ER progenitor cells can transdifferentiate into basal
progenitor cells as part of a normal physiological process, either directly
(depicted by arrow with a question mark) or first via dedifferentiation to a
bipotent progenitor/stem cell.
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Previewsoutgrowths containing both
luminal and basal cell types
in the cleared mammary fat
pad.
One interpretation of these
data is that luminal ER- pro-
genitor cells can display a
capacity for context-depen-
dent multilineage differentia-
tion. While this conclusion is
reasonable, it seems equally
plausible that the antigen
profile used to enrich luminal
ER progenitor cells might
also include bipotent progen-
itor cells. If so, it might be the
case that BRCA1 mutations
actually occur in a bipotent
progenitor cell that subse-
quently enters exclusively into
thecommitted luminalprogen-
itor lineage. This possibility
would account for the expan-
sion of a luminal-progenitor
cell population described in
this work by Molyneux and
other recent work showing
that luminal progenitor num-
bers are increased in the
breast tissue of BRCA1 muta-
tion carriers (Lim et al., 2009).
If this were the case, it is
feasible that the earlier work
defining the mammary stem/
progenitor cell as the BRCA1breast cancer cell of origin could be
reconciled with the new findings pre-
sented in this issue by concluding that
both groups have identified the same
cell of origin, yet labeled it differently.
That conclusion has some support in
data reported by Molyneux in directly
comparing the gene signatures of Blg-
Cre Brca1f/f p53+/ (asserted byMolyneux
to target a luminal cell population) and
K14-Cre Brca1f/f p53+/ (asserted by Mo-
lyneux to target a basal-cell population)
tumors and demonstrating that both
tumor types most closely resembled the
normal cell type they classified as luminal
ER- cells, and thus did not fall into
different subgroups.
Perhaps the key to interpreting these
novel findings lies in a degree of cellular
plasticity that is thought to be largely
confined to mammary stem cells. The272 Cell Stem Cell 7, September 3, 2010 ª20current depiction of the conventional
stem cell hierarchy suggests that stem
cells can undergo asymmetric division to
create nonstem daughters. Conversely,
nonstem cells are portrayed as being
unable to move back up the hierarchy
and dedifferentiate into a stem cell state.
However, if (as the authors suspect) non-
stem cells did indeed have this ability, via
either a normal cellular process or a
consequence of genetic alterations (such
as those associated with tumorigenesis),
it is possible that luminal progenitor cells
acquiring a BRCA1 mutation might
undergo a degree of dedifferentiation,
allowing them to revert to a bipotent
progenitor or even an oligopotent stem
cell state (both of which states exhibit
basal characteristics). In this event,
luminal progenitor cells would be able to
give rise to carcinomas with a basal10 Elsevier Inc.phenotype (via conversion
to a bipotent progenitor or
stem cell).
In accord with the idea pre-
sented by Molyneux et al.,
another group recently dem-
onstrated that a basal cell
might also be the cell of origin
in a model of prostate cancer,
a disease characterized by
luminal cell expansion and
the absence of basal cells
(Goldstein et al., 2010). These
findings lend further support
to the emerging theme that
the histology of cancer does
not always reflect the nature
of the cell of origin. Identifying
the target cells of transforma-
tion is key to understanding
the pathogenesis of these
common human tumors.
Such information may also
prove critical to developing
more powerful diagnostic
and prognostic tools than
are currently available.REFERENCES
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